12 completed, 1 terminated. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 12, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow HIV Seropositivity: new trials by email Literature Review of HIV Seropositivity trials Research Report on HIV Seropositivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection SARS-Cov-2 neutralizing antibody titer - Vaccine Adverse Reaction, Seroconversion | Phase 3 | Completed | Zagazig University | 246 | 2021-02-11 | 2022-02-09 |
| Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh. Hepa-B, Engerix B - Hepatitis B Infection | Phase 2 / Phase 3 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 158 | 2018-07-29 | 2022-02-11 |
| Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen Raltegravir, Lamivudine - HIV Seropositivity, HIV Infections | Phase 3 | Terminated | Judit Pich | 17 | 2018-05-03 | 2025-05-18 |
| Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Raltegravir, Lamivudine - HIV Infections, HIV-1-infection | Phase 3 | Completed | Judit Pich | 33 | 2018-05-02 | 2025-07-18 |
| Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea Crofelemer - HIV Enteropathy, Diarrhea With HIV | Phase 3 | Completed | Bausch Health Americas, Inc. | 250 | 2011-06-07 | 2020-08-31 |
| Positive Change Agents Program-Tanzania (Evaluation) Appreciative Inquiry Change Agents (CA) program (NAMWEZA) - HIV Infection | Phase 3 | Completed | Harvard School of Public Health (HSPH) | 1046 | 2011-04-01 | 2015-10-20 |
| An Evaluation of a Rapid Test for HIV Rapid testing for HIV - HIV Seropositivity | Phase 3 | Completed | Pontificia Universidad Catolica de Chile | 497 | 2010-05-01 | 2012-11-27 |
| Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF), Placebo - HIV-1 Infections, HIV Infections | Phase 3 | Completed | University of Washington | 4758 | 2008-05-01 | 2019-04-19 |
| Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay collection of follow-up sample based on PRISM HIV O Plus result - Healthy Donors, HIV Positive | Phase 3 | Completed | Abbott Diagnostics Division | 24111 | 2007-08-01 | 2011-12-28 |
| Comparison of Treatment Simplification by LPV/r vs Current Treatment Continuation in HIV-Infected Patients Lopinavir/ritonavir (drug) - HIV Infections | Phase 3 | Completed | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | 186 | 2005-10-01 | 2013-09-19 |
| Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission Carraguard (PC-515) - HIV Infections, AIDS | Phase 3 | Completed | Population Council | 6203 | 2004-04-01 | 2017-08-15 |
| Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV) Lamivudine plus Polyethylene glyco-interferon alfa-2b, Lamivudine - Chronic Hepatitis B | Phase 3 | Completed | GlaxoSmithKline | 160 | 2000-04-01 | 2008-10-16 |
| Motivation and Patch Treatment for HIV-positive Smokers Standard Care, Motivational Enhancement - HIV Infections, Smoking Cessation | Phase 3 | Completed | National Institute on Drug Abuse (NIDA) | 444 | 1999-01-01 | 2017-01-12 |
HIV Infections (7) · Acquired Immunodeficiency Syndrome (3) · Hepatitis B (2) · Bronchiolitis Obliterans Syndrome (1) · Coitus (1) · Diarrhea (1) · HIV Enteropathy (1) · Hepatitis B, Chronic (1) · Safe Sex (1) · Sexually Transmitted Diseases (1) · Smoking (1) · Smoking Cessation (1)
Blood-Borne Infections (13) · Communicable Diseases (13) · Genital Diseases (13) · Immune System Diseases (13) · Immunologic Deficiency Syndromes (13) · Infections (13) · Lentivirus Infections (13) · RNA Virus Infections (13) · Retroviridae Infections (13) · Sexually Transmitted Diseases, Viral (13) · Urogenital Diseases (13) · Virus Diseases (13) · Sexually Transmitted Diseases (12) · HIV Infections (6) · Digestive System Diseases (3)
Lamivudine (3) · Raltegravir Potassium (2) · Emtricitabine (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Engerix-B (1) · Lopinavir (1) · Pharmaceutical Preparations (1) · Ritonavir (1) · Standard of Care (1) · Tenofovir (1) · crofelemer (1)
Judit Pich (2) · Abbott Diagnostics Division (1) · Bausch Health Americas, Inc. (1) · GlaxoSmithKline (1) · Harvard School of Public Health (HSPH) (1) · Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · National Institute on Drug Abuse (NIDA) (1) · Pontificia Universidad Catolica de Chile (1) · Population Council (1) · University of Washington (1) · Zagazig University (1)
United States (3) · Spain (2) · Bangladesh (1) · Chile (1) · Egypt (1) · France (1) · Hong Kong (1) · Kenya (1) · South Africa (1) · Tanzania (1) · Uganda (1)
Connie Celum,, MD, MPH (1) · Elizabeth Lloyd-Richardson, PhD (1) · Firdausi Qadri, PhD (1) · Jared Baeten, MD, PhD (1) · Lisette P Irarrazabal, PhD © (1) · Mary C. Smith Fawzi, ScD (1) · Noha M Hammad, MD (1) · Pekka Lahteenmaki, MD, PhD (1) · Raymond Niaura, PhD (1)
PMID 19059048, PMID 19719796, PMID 20843990, PMID 20949113, PMID 22784037, PMID 23939368, PMID 24979446, PMID 25038355, PMID 25300863, PMID 25531343, PMID 27029778, PMID 29108000, PMID 29201750, PMID 29767684, PMID 30297124, PMID 31179027, PMID 31996246, PMID 33033007, PMID 34561142, PMID 34929030, PMID 39101506
2017 (2)